VERV Stock Overview
A clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Verve Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.85 |
| 52 Week High | US$19.34 |
| 52 Week Low | US$4.31 |
| Beta | 1.76 |
| 11 Month Change | -18.76% |
| 3 Month Change | -5.09% |
| 1 Year Change | -59.98% |
| 33 Year Change | -85.37% |
| 5 Year Change | n/a |
| Change since IPO | -84.81% |
Recent News & Updates
Recent updates
Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio
Aug 30Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78
Aug 10
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Jul 12Why Verve Therapeutics Deserves A Spot On Your Watchlist
Jun 13Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher
May 14The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17Shareholder Returns
| VERV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.3% | 2.5% | 2.2% |
| 1Y | -60.0% | 16.1% | 31.6% |
Return vs Industry: VERV underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: VERV underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| VERV volatility | |
|---|---|
| VERV Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VERV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VERV's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 255 | Sek Kathiresan | www.vervetx.com |
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company’s lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.
Verve Therapeutics, Inc. Fundamentals Summary
| VERV fundamental statistics | |
|---|---|
| Market cap | US$410.62m |
| Earnings (TTM) | -US$197.03m |
| Revenue (TTM) | US$24.40m |
16.8x
P/S Ratio-2.1x
P/E RatioIs VERV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VERV income statement (TTM) | |
|---|---|
| Revenue | US$24.40m |
| Cost of Revenue | US$196.11m |
| Gross Profit | -US$171.71m |
| Other Expenses | US$25.31m |
| Earnings | -US$197.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.33 |
| Gross Margin | -703.86% |
| Net Profit Margin | -807.62% |
| Debt/Equity Ratio | 0% |
How did VERV perform over the long term?
See historical performance and comparison